Join
Live feed
·
PRReleasevia Quantisnow
Prelude Therapeutics Incorporated logo

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
PRLD· Prelude Therapeutics Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRLD (Prelude Therapeutics Incorporated) and more on Quantisnow.